文献速递前列腺增生与排尿功能障碍男科与性医学

接受5α还原酶抑制剂或α受体阻滞剂治疗良性前列腺增生的老年男性自杀与故意自伤研究

Suicide and Intentional Self-harm Among Older Men Treated With 5-Alpha Reductase Inhibitor or Alpha-blockers for Benign Prostatic Hyperplasia.
PubMed 文献 · Urology · 2024-06-15

基于2007至2016年Medicare与全国死亡索引链接数据,对≥65岁因良性前列腺增生起始5α还原酶抑制剂或α受体阻滞剂的男性进行回顾性队列分析。5α还原酶抑制剂组故意自伤与自杀风险较α受体阻滞剂组均未升高,复合结局风险亦无显著差异。

要点

  • 5α还原酶抑制剂组故意自伤发生率为0.314/1000人年,α受体阻滞剂组为0.364/1000人年。
  • 5α还原酶抑制剂组自杀发生率为0.308/1000人年,α受体阻滞剂组为0.382/1000人年。
  • 与α受体阻滞剂相比,5α还原酶抑制剂故意自伤HR 0.88(95%CI 0.62-1.25),自杀HR 0.82(95%CI 0.54-1.24),复合结局HR 0.88(95%CI 0.66-1.16)。

核心结论

  • 在良性前列腺增生老年男性中,与α受体阻滞剂相比,5α还原酶抑制剂使用与故意自伤或自杀风险增加无关。

研究设计与样本

  • 采用回顾性队列设计,使用2007至2016年Medicare数据链接全国死亡索引,纳入因良性前列腺增生起始5α还原酶抑制剂或α受体阻滞剂治疗的≥65岁男性。

主要发现

  • 5α还原酶抑制剂组(n=181,675)故意自伤和自杀发生率分别为0.314和0.308/1000人年,α受体阻滞剂组(n=850,476)分别为0.364和0.382/1000人年。
  • 5α还原酶抑制剂相对α受体阻滞剂,故意自伤HR 0.88(95%CI 0.62-1.25),自杀HR 0.82(95%CI 0.54-1.24),复合结局(非致命故意自伤或自杀)HR 0.88(95%CI 0.66-1.16)。
  • 亚组和敏感性分析支持上述结果。

关键数值与推荐

  • 故意自伤通过ICD-9-CM和ICD-10-CM诊断编码识别,自杀通过全国死亡索引死因信息识别。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括事件发生率低以及对故意自伤事件的敏感性可能较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of intentional self-harm (ISH) and suicide in older men using 5-α reductase inhibitors (5-ARIs) and alpha-blockers for benign prostatic hyperplasia (BPH). Observational research of older men with BPH suggested an increase in ISH with 5-ARI use compared with nonuse; we aimed to address potential confounding by indication with an active comparator reference group. METHODS: Using Medicare data linked to the National Death Index (NDI) from 2007-2016, we implemented a retrospective cohort design in males aged ≥65 years who initiated 5-ARI or alpha-blocker use for BPH. ISH was identified using ICD-9-CM and ICD-10-CM diagnosis codes. Suicides were identified through cause-of-death information from the NDI. We used inverse probability of treatment weighted Cox proportional hazards regression to compare time-to-event between treatment groups, with robust variance estimation. RESULTS: The event rates for ISH and suicide, respectively, were 0.314 and 0.308 per 1000 person-years (PY) among 5-ARI users (n = 181,675), and 0.364 and 0.382 per 1000PY among alpha-blocker users (n = 850,476). For 5-ARI use relative to alpha-blocker use, hazard ratios (HRs) for ISH and suicide, respectively, were 0.88 (95% CI:0.62-1.25) and 0.82 (95% CI:0.54-1.24); for the composite outcome (non-fatal ISH or suicide), the HR was 0.88 (95% CI:0.66-1.16). Subgroup and sensitivity analyses supported these results. CONCLUSION: 5-ARI use was not associated with an increased risk for ISH or suicide compared to alpha-blocker use in older men with BPH. Study limitations included low event rates and potentially low sensitivity for ISH events.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Pennap D, Mosholder AD, Ajao A, et al. Suicide and Intentional Self-harm Among Older Men Treated With 5-Alpha Reductase Inhibitor or Alpha-blockers for Benign Prostatic Hyperplasia. Urology. 2024. PMID: 38880345. doi:10.1016/j.urology.2024.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。